Title
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure
Phase
Phase 2/Phase 3Lead Sponsor
Onassis Cardiac Surgery CentreStudy Type
InterventionalStatus
Completed No Results PostedIntervention/Treatment
iloprost ...Study Participants
208The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.
Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
Inclusion Criteria: Patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was <60 ml/min on their most recent sample drawn within 1 month of the planned procedure Exclusion Criteria: Circulatory shock for any reason, systolic blood pressure <95 mm Hg Known acute renal failure End-stage renal disease requiring dialysis Intravascular administration of a contrast medium within the previous 10 days Anticipated re-administration of contrast medium within the following 6 days Inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure Primary intervention for acute infarction with ST elevation A procedure performed within 2 h of acute hospital admission
